Back to today’s briefing

Story perspectives

Novo Nordisk Sues Eli Lilly Over Zepbound Ads

8/13/2026

22 3 Full Breakdown

Summary

Story summary

Novo Nordisk CEO Mike Doustdar sued Eli Lilly, alleging its ads compare Zepbound to a lower-dose Wegovy.
Eli Lilly spokesperson said the ads are truthful and no trial supports a claim Wegovy HD matches Zepbound.
Since the filing, Novo shares fell 6% while Eli Lilly shares rose nearly 4%.
Lilly’s Foundayo received FDA approval on April 1 after a May 2025 study reported Zepbound 10-15 mg caused 20.2% weight loss versus 13.7% for Wegovy 1.7-2.4 mg.

1 of 1

Story summary

Novo Nordisk CEO Mike Doustdar sued Eli Lilly, alleging its ads compare Zepbound to a lower-dose Wegovy.
Eli Lilly spokesperson said the ads are truthful and no trial supports a claim Wegovy HD matches Zepbound.
Since the filing, Novo shares fell 6% while Eli Lilly shares rose nearly 4%.
Lilly’s Foundayo received FDA approval on April 1 after a May 2025 study reported Zepbound 10-15 mg caused 20.2% weight loss versus 13.7% for Wegovy 1.7-2.4 mg.